IL-17 Inhibition in Spondyloarthritis: A Targeted Approach in Psoriatic Arthritis - European Medical Journal
×

Browse

IL-17 Inhibition in Spondyloarthritis: A Targeted Approach in Psoriatic Arthritis

|
Rheumatology
Download as | PDF
Chairpeople:
Philip Mease1
Speakers:
Erik Lubberts,2 Iain McInnes,3 Désirée van der Heijde4
Disclosure:

Philip Mease has received research grants, consultation fees and/or speaker honoraria from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB; Erik Lubberts has received support from Novartis, Roche, Janssen, AbbVie, NTRC, Ensemble Therapeutics Group, and Pieris AG; Iain McInnes has received research funding and honoraria from Janssen, Eli Lilly, Amgen, Pfizer, Bristol-Myers Squibb, and Novartis; Désirée van der Heijde has received consulting fees and/or research grants from AbbVie, Amgen, AstraZeneca, Augurex, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli Lilly, Galapagos, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, UCB, and Vertex, and is a director of Imaging Rheumatology BV.

Acknowledgements:

Writing assistance was provided by Dr Jill Powell, apothecom scopemedical Ltd.

Support:

The publication of this article was funded by Novartis. The views and opinions expressed are those of the authors and not necessarily of Novartis.

Citation
EMJ Rheumatol. ;2[1]:55-64.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

Prof Philip Mease introduced psoriatic arthritis (PsA) with a particular emphasis on disease symptoms and an update on the status of current disease management. Erik Lubberts described the interleukin (IL)-17 pathway and its role in the pathogenesis of PsA. Prof Iain McInnes reviewed the clinical evidence for the efficacy of IL-17 inhibition in PsA. Prof Désirée van der Heijde brought the symposium to a close with a presentation on the clinical impact of joint structural damage and strategies for its prevention in PsA.

Please view the full content in the pdf above.